去纤苷注意事项有什么?
It is suitable for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). What are the precautions for using defibrotide?
1. Defibrotide needs to be administered by injection, and defibrotide must be diluted before infusion.
2. Before administration of defibrotide, confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.
3. Do not co-administer defibrotide and other intravenous drugs in the same intravenous line at the same time.
4. Bleeding
Defibrinoside increases plasmin activity in vitro, and sputum may increase the risk of bleeding after hematopoietic stem cell transplantation (HSCT) in patients with VOD. Do not initiate defibrotide in patients with active bleeding. Monitor patients for signs of bleeding and, if bleeding occurs while taking defibrotide, discontinue defibrotide, treat the cause, and provide supportive care until bleeding has ceased. See Dosage and Administration.
Concomitant use of defibrotide and a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding.
Discontinue anticoagulants and fibrinolytics before defibrotide therapy, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.
5. Hypersensitivity reaction
Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide. These reactions included rash, urticaria, and angioedema, and were reported in a case of anaphylactic reaction in a patient who had previously received defibrotide. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue, treat and monitor with standard medical care until symptoms resolve.
Recommended related hot articles: /newsDetail/74941.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)